Ipamorelin

Overview

Ipamorelin is a synthetic pentapeptide in the class of growth hormone secretagogues. It binds to the ghrelin / growth hormone secretagogue receptor (GHS-R1a) and stimulates the release of growth hormone from the anterior pituitary. It was developed in the 1990s by Novo Nordisk and is derived from GHRP-1, under the development code NNC 26-0161.

What distinguishes Ipamorelin in the literature is its selectivity. Related secretagogues such as GHRP-6 and GHRP-2 also raise ACTH and cortisol; in animal models Ipamorelin does not, even at doses well over two hundred times the dose needed for growth hormone release. That clean separation between the intended signal and the broader endocrine effects is the primary reason for sustained scientific interest.

Unlike many other compounds in this database, Ipamorelin has actually been studied in humans, in two randomised trials. The picture that emerges is nuanced: the peptide was well tolerated, but in the one clinical efficacy study it did not meet its primary endpoint. That distinction runs through this profile.

Mechanism of action

Ipamorelin binds to the GHS-R1a receptor on the somatotroph cells of the anterior pituitary and stimulates the pulsatile release of growth hormone. It acts through a route distinct from growth hormone-releasing hormone (GHRH) and thus forms a complementary input on the same outcome.

Ghrelin receptor signalling

• Selective binding to the GHS-R1a receptor.
• Stimulation of pulsatile growth hormone release from somatotroph cells.
• Complementary to the GHRH-mediated route of growth hormone release.

Selectivity profile

• In animal models, no notable rise in cortisol, even at very high doses.
• No notable rise in prolactin, unlike related secretagogues.
• Dose-dependent growth hormone release without broad disruption of other pituitary hormones.

What the mechanism does not say

• A clean receptor profile under controlled conditions does not automatically predict a clinical effect, as the human efficacy trial demonstrated.
• The downstream effects of the induced growth hormone pulse on functional outcomes are only partially characterised.

Research findings

• Dose-dependent, short-lived growth hormone pulse in healthy human volunteers (PK/PD RCT)
• Phase II trial in postoperative ileus: safe and well tolerated, but did not meet the primary endpoint (n=117)
• Dose-dependent longitudinal bone growth in rats without changes in IGF-1 or bone turnover markers
• Counteracted glucocorticoid-induced loss of bone formation and muscle strength in rats
• Original characterisation: GH release without ACTH/cortisol elevation

Human studies

• In a randomised PK/PD study in healthy volunteers, ipamorelin produced a dose-dependent, short-lived growth hormone pulse with a terminal half-life of approximately two hours (Gobburu 1999).
• In a randomised, double-blind, placebo-controlled phase II study in 117 patients after bowel resection, ipamorelin was safe and well tolerated, but the time to first tolerated meal did not differ significantly from placebo (Beck 2014). The primary endpoint was not met.

Animal models

• In rats, ipamorelin dose-dependently increased longitudinal bone growth without changing total IGF-1 levels or bone turnover markers (Johansen 1999).
• In a rat model, ipamorelin counteracted glucocorticoid-induced loss of bone formation and muscle strength (Andersen 2001).
• In a rat model of postoperative ileus, repeated administration accelerated gastrointestinal transit and improved food intake (Venkova 2009).
• In a ferret model, ipamorelin attenuated cisplatin-induced weight loss (Lu 2024).

Characterisation and selectivity

• The original characterisation showed growth hormone potency comparable to GHRP-6, but without the ACTH and cortisol release that GHRP-6 and GHRP-2 do evoke (Raun 1998).

Research context

Ipamorelin holds a special place within this database: it is one of the few compounds with a completed clinical research programme. That sharpens the picture relative to purely preclinical peptides, and makes it more sober.

The strength of ipamorelin lies in its selectivity. The separation between growth hormone release and the broader stress axis (ACTH, cortisol) is well documented, and that makes it a valuable instrument for studying GHS-R1a signalling and pulsatile growth hormone biology. As a pharmacological tool, the profile is unusually clean.

The limit of what the peptide can do is, however, equally well documented. In the one clinical efficacy study, a phase II trial in postoperative ileus, ipamorelin was safe but did not meet its primary endpoint. Development for that indication was discontinued. That is an important fact: a favourable receptor profile and consistent animal data did not translate, here, into a demonstrable clinical effect. It illustrates exactly why mechanistic clarity and clinical efficacy must be judged independently.

A final caveat concerns the relationship between the science and online discussion. Ipamorelin is widely discussed outside the literature, and that discussion often reaches considerably further than what the published evidence supports. The factual base is a clean preclinical profile, two human RCTs, and a missed clinical endpoint.

Open questions

• Clinical efficacy has not been demonstrated in the indication studied; for other indications no efficacy data exist.
• Long-term effects of chronic administration have not been characterised.
• Varying study designs make cross-study comparison difficult.
• Translation of changes in endocrine markers into functional outcomes is uncertain; the phase II trial illustrates this.
• Bioavailability and pharmacokinetics across different administration routes require further investigation.

Research outlook

Controlled human studies with modern trial designs and well-defined clinical endpoints.

Dose-response characterisation across age groups and physiological contexts.

Combination research with GHRH analogs and other secretagogues.

Assessment of the long-term safety profile and systemic impact.

Clarification of the relationship between growth hormone marker changes and functional outcomes.

Scientific interest

Highly selective growth hormone secretagogue with minimal cortisol and prolactin interference, a rare profile among growth hormone peptides.

Research tool for studying GHS-R1a signalling and pulsatile growth hormone biology.

Possible synergy with GHRH analogs in combination research.

The contrast between a clean mechanistic profile and a missed clinical endpoint.

Specifications

References

1. Ipamorelin, the first selective growth hormone secretagogue · Raun K, Hansen BS, Johansen NL, et al. · Eur J Endocrinol · 1998
2. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats · Johansen PB, Nowak J, Skjaerbaek C, et al. · Growth Horm IGF Res · 1999
3. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers · Gobburu JV, Agersø H, Jusko WJ, Ynddal L · Pharm Res · 1999
4. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats · Andersen NB, Malmlöf K, Johansen PB, et al. · Growth Horm IGF Res · 2001
5. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus · Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B · Journal of Pharmacology and Experimental Therapeutics · 2009
6. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients · Beck DE, Sweeney WB, McCarter MD, et al. · Int J Colorectal Dis · 2014
7. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets · Lu Z, Ngan MP, Liu JYH et al. · Physiology & Behavior · 2024

Availability

Not in catalogue · Profile complete · verification and sourcing not yet finished